U.S. Adult โObesity Rateโ Declines as Weight-Loss Drugs Drive Marketโฃ Surge
New York,NYโฃ – October 31,2025 – โIn a potential turning point for public health,teh U.S. adult obesityโ rate hasโข begun to fall from its recordโ high, coinciding with the increasing โmainstream adoption of blockbuster weight-loss drugs like Zepbound and Mounjaro. The shift is fueling aโข massive boom for pharmaceutical companies, with the obesity drug market projectedโ to reachโ $150 โbillion by 2030.
The decline in obesity rates signals a possible โคnew era in combating aโค decades-long health crisis affecting over 40% of โขAmerican adults. However, access and affordabilityโ remainโ key challenges as demand for these medications-and theโ competition to supply them-intensifies.The burgeoning market is attracting aggressive moves from major โplayers, including Eliโข Lilly and Novo Nordisk, as they vie for dominance in a โคrapidly evolving landscape.
Eli Lilly reported stellar third-quarter earnings โฃyesterday, raising its full-year revenue estimates โฃto $63 billion-$63.5 billion, a notableโ increase from its previousโ forecast โคof โข$60 billion-$62 billion. The company attributesโข this growth to the rising popularity โขof Zepbound and Mounjaro. To โfurther โexpand access, Eli lilly has partnered with โฃWalmart to offer single-dose vials of Zepbound โคfor under $500 in pharmacies nationwide.
Meanwhile,โค novo Nordisk, the creator of Wegovy and ozempic, is locked in a bidding war for Metsera,โฃ a biotech firm developing next-generation GLP-1 drugs. Novo Nordisk recently โฃmade an unsolicited offer of $9 billion for Metsera, surpassing a โprevious agreement for the company to be acquired by Pfizer for up to $7.3 billion. Metsera’s pipeline includes GLP-1s designed for less frequent administration,โค perhapsโ offering greater convenience for patients.
The escalating competition underscores the high โstakes in the weight-loss drug market, as pharmaceutical companiesโฃ race to innovate โand captureโ market share in what is becoming one of the moastโฃ lucrative sectors in healthcare.
